Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Accumulated Expenses: 2019-2023

Historic Accumulated Expenses for ADC Therapeutics (ADCT) over the last 3 years, with Sep 2023 value amounting to $53.5 million.

  • ADC Therapeutics' Accumulated Expenses fell 14.64% to $53.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $53.5 million, marking a year-over-year decrease of 14.64%. This contributed to the annual value of $68.5 million for FY2022, which is 35.63% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Accumulated Expenses is $53.5 million, which was up 0.16% from $53.4 million recorded in Q2 2023.
  • ADC Therapeutics' Accumulated Expenses' 5-year high stood at $68.5 million during Q4 2022, with a 5-year trough of -$791 in Q2 2022.
  • For the 3-year period, ADC Therapeutics' Accumulated Expenses averaged around $43.7 million, with its median value being $50.5 million (2021).
  • Per our database at Business Quant, ADC Therapeutics' Accumulated Expenses crashed by 100.00% in 2022 and then spiked by 6,750,668.90% in 2023.
  • Quarterly analysis of 5 years shows ADC Therapeutics' Accumulated Expenses stood at $15.4 million in 2019, then reached $22,633 in 2020, then skyrocketed by 175,241.32% to $50.5 million in 2021, then soared by 35.63% to $68.5 million in 2022, then dropped by 14.64% to $53.5 million in 2023.
  • Its Accumulated Expenses stands at $53.5 million for Q3 2023, versus $53.4 million for Q2 2023 and $57.4 million for Q1 2023.